Moirai Biodesign SL

Moirai Biodesign SL is a biotechnology firm based in Barcelona, Spain, specializing in advanced diagnostics technology and RNA design software for innovative applications in biomedicine. Founded in 2016 in Barcelona, Spain, Moirai Biodesign SL focuses on the development of biomedicine technology. The company has pursued three notable deals, with its most recent investment round occurring on December 18, 2019, when it raised seed funding from RebelBio and SOSV. The CEO and co-founder, Amadís Pagès, has a background in biotechnology entrepreneurship.

Moirai Biodesign specializes in advanced biomedicine, focusing on the development of cutting-edge diagnostics technology and RNA design software. Their primary offerings include state-of-the-art diagnostics tools capable of detecting RNA in diverse settings, from Point of Care applications to High-throughput laboratory environments. Additionally, the company has designed AI-driven algorithms for the creation of small RNA molecules and long mRNA molecules intended for therapeutic and investigational purposes. These products aim to address critical needs in the biomedicine sector, facilitating the early detection of diseases and contributing to the development of novel RNA-based therapies.

Moirai Biodesign targets various geographical markets, including but not limited to Europe and North America, where they serve a wide range of clients, from healthcare institutions to research laboratories. Moirai Biodesign generated revenue of USD 38,641. 50 in 2023, with an EBITDA of USD 4,222. 60 for the same year.

The company generates revenue through direct sales and partnerships with healthcare providers and research institutions, engaging in B2B transactions by supplying its diagnostic technology and RNA design software to clients such as laboratories and pharmaceutical companies. Revenue streams are structured around sales of proprietary products and software licenses, as well as potential subscription models for continued access to their RNA design tools. Moirai Biodesign plans to expand its portfolio by launching new products designed to enhance its current offerings and meet emerging market needs. The company aims to enter new markets throughout Europe and North America by 2025.

Recent funding raised in December 2019 from RebelBio and SOSV will support these initiatives, facilitating research and development efforts to drive product innovation and market penetration.